Photo: Courtesy of Eli Lilly
Eli Lilly has filed a complaint against Aurobindo Pharma for allegedly infringing a patent covering the drug Cialis (tadalafil).
Cialis is a treatment for patients with erectile dysfunction and symptoms of benign prostatic hypertrophy, an enlarged prostate gland.
The case, which was filed in the US District Court for the Eastern District of Virginia on September 2, arose after Aurobindo sought approval of an Abbreviated New Drug Application (ANDA) from the Food and Drug Administration to market a generic version of Cialis.
Aurobindo notified Eli Lilly that it had submitted the ANDA on May 19, 2014, while it also asserted that Eli Lilly’s US patent number 6,943,166 is invalid.
Eli Lilly has asked the court to stop Aurobindo’s ANDA from being approved before the expiration date of the patent involved.
It is not the first time Eli Lilly has sued Aurobindo for patent infringement. Back in 2008, the company took action over its drug Cymbalta (duloxetine), a treatment for depression.
Eli Lilly, Aurobindo, Cialis, tadalafil, ANDA, FDA, patent
